Corbus PharmaceuticalsCRBP
CRBP
About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Employees: 19
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
95% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 20
21% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $18.9M
0% more funds holding
Funds holding: 107 [Q2] → 107 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
5.31% less ownership
Funds ownership: 103.0% [Q2] → 97.69% (-5.31%) [Q3]
51% less capital invested
Capital invested by funds: $498M [Q2] → $243M (-$255M) [Q3]
67% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 2 (-4) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
129%
upside
Avg. target
$60
294%
upside
High target
$82
436%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Biren Amin 24% 1-year accuracy 4 / 17 met price target | 129%upside $35 | Overweight Initiated | 2 Dec 2024 |
HC Wainwright & Co. Andrew Fein 33% 1-year accuracy 52 / 158 met price target | 423%upside $80 | Buy Reiterated | 23 Sept 2024 |
B. Riley Securities Kalpit Patel 83% 1-year accuracy 5 / 6 met price target | 161%upside $40 | Buy Maintained | 20 Sept 2024 |
Wedbush Robert Driscoll 35% 1-year accuracy 19 / 55 met price target | 233%upside $51 | Outperform Maintained | 20 Sept 2024 |
Mizuho Graig Suvannavejh 65% 1-year accuracy 13 / 20 met price target | 384%upside $74 | Outperform Reiterated | 20 Sept 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload.
Neutral
Seeking Alpha
3 weeks ago
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway.
Neutral
GlobeNewsWire
1 month ago
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA.
Neutral
GlobeNewsWire
1 month ago
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg) and will be followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommended/optimized doses and seek preliminary efficacy signals.
Neutral
24/7 Wall Street
2 months ago
Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.
Neutral
GlobeNewsWire
2 months ago
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets' Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.
Negative
Benzinga
2 months ago
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
Corbus Pharmaceuticals Holdings, Inc. CRBP received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s NVO mid-stage data on its obesity drug.
Negative
Investors Business Daily
2 months ago
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.
Positive
24/7 Wall Street
2 months ago
3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.
Positive
Market Watch
3 months ago
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.
Charts implemented using Lightweight Charts™